Orkla India Limited has made a regulatory disclosure regarding the grant of employee stock options under its Employee Stock Option Plan 2025 (ESOP 2025).
Key Quantitative Figures
The company has granted 11,11,850 (Eleven Lakh Eleven Thousand Eight Hundred and Fifty) employee stock options. Each option is exercisable into one fully paid-up equity share of the company, subject to adjustments under the plan.
The exercise price has been set at ₹702.90 (Rupees Seven Hundred Two and Paise Ninety only) per option. This price was determined with reference to the closing market price of ₹528.10 per equity share on the National Stock Exchange (NSE) on 4th November 2026.
Dates of Action
The Nomination and Remuneration Committee of the Board of Directors approved the grant via a circular resolution passed on 5th November 2026. The disclosure was made to the exchanges on 6th November 2026.
Parties Involved
The grant was approved by the Nomination and Remuneration Committee of Orkla India Limited. The disclosure was signed by Kaushik Seshadri, Company Secretary and Compliance Officer.
Terms and Conditions
The options have a fixed vesting period of 3 years from the grant date, which includes the minimum vesting period of 1 year prescribed under applicable law. Vesting is subject to continued employment and satisfaction of conditions specified in ESOP 2025 and respective grant letters.
During employment, vested options may be exercised within 2 years from the relevant vesting date.
Financial Impact
Not quantified in the disclosure. The potential dilution impact would occur only upon exercise of the options in the future.
Additional Information
The company's registered office is at No. 1, 2nd & 3rd Floor, 100 Feet Inner Ring Road, Ejipura, Ashwini Layout, Vivek Nagar, Bengaluru - 560 047, India. The CIN is L15136KA1996PLC021007.
The information will be made available on the company's website at https://www.orklaindia.com/investor-relations/.